Susan L. Cohn
University of Chicago
280 Papers
2.6K Citations
Susan L. Cohn is an academic researcher from University of Chicago. The author has contributed to research in topics: Neuroblastoma & Medicine. The author has an hindex of 71, co-authored 268 publications. Previous affiliations of Susan L. Cohn include Johns Hopkins University School of Medicine & Northwestern University.
Chat about Author
Papers
Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
Murray D. Norris,Sharon B. Bordow,Glenn M. Marshall,Paul S. Haber,Susan L. Cohn,Michelle Haber +5 more
TL;DR: High levels of MRP gene expression in patients with neuroblastoma correlate strongly with poor outcome, and expression of this multidrug-resistance gene accounts for the association between N-myc amplification and reduced survival.
323
Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project
Wendy B. London,Victoria Castel,Tom Monclair,Peter F. Ambros,Andrew D.J. Pearson,Susan L. Cohn,Frank Berthold,Akira Nakagawara,Ruth Ladenstein,Tomoko Iehara,Katherine K. Matthay +10 more
TL;DR: Age, stage, MYCN status, and TTFR are significant prognostic factors for postrelapse survival and may help in the design of clinical trials evaluating novel agents.
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial
Susan G. Kreissman,Robert C. Seeger,Katherine K. Matthay,Wendy B. London,Wendy B. London,Richard Sposto,Stephan A. Grupp,Daphne A. Haas-Kogan,Michael P. LaQuaglia,Alice L. Yu,Lisa Diller,Allen Buxton,Julie R Park,Susan L. Cohn,John M. Maris,C. Patrick Reynolds,Judith G. Villablanca +16 more
TL;DR: A randomised study of tumour-selective PBSC purging in stem-cell transplantation for patients with high-risk neuroblastoma and the primary endpoint was event-free survival, which was analysed by intention-to-treat.
298
Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma
David L. Baker,Mary Lou Schmidt,Susan L. Cohn,John M. Maris,Wendy B. London,Allen Buxton,Daniel O. Stram,Robert P. Castleberry,Hiroyuki Shimada,Anthony D. Sandler,Robert C. Shamberger,A. Thomas Look,C. Patrick Reynolds,Robert C. Seeger,Katherine K. Matthay +14 more
TL;DR: A very high rate of survival among patients with intermediate-risk neuroblastoma was achieved with a biologically based treatment assignment involving a substantially reduced duration of chemotherapy and reduced doses of chemotherapeutic agents as compared with the regimens used in earlier trials.
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
Julie R. Park,Julie R. Park,Susan G. Kreissman,Wendy B. London,Arlene Naranjo,Susan L. Cohn,Michael D. Hogarty,Sheena C. Tenney,Daphne A. Haas-Kogan,Peter J. Shaw,Jacqueline M. Kraveka,Stephen S. Roberts,James Duncan Geiger,John J. Doski,Stephan D. Voss,John M. Maris,Stephan A. Grupp,Lisa Diller +17 more
TL;DR: T tandem autologous transplant resulted in a significantly better EFS than single transplant among patients aged 30 years or younger with high-risk neuroblastoma, however, because of the low randomization rate, the findings may not be representative of all patients withhigh-risk Neuroblastoma.